Great News for Celator That Might Be Great News for Jazz Pharmaceuticals

Good News That Might Go to JAZZ Pharmaceuticals
Celator Pharmaceuticals (CPXX): At the European Hematology Association (EHA) 21st Annual Congress, Celator  presented positive response rate results in acute myeloid leukemia (AML) patients with the FLT3 (FMS-like tyrosine kinase-3) mutation.   The results came from Phase 3 trial of VYXEOS™ (cytarabine: daunorubicin) Liposome for Injection in patients with high-risk (secondary) acute myeloid leukemia (AML).

Data, demonstrated VYXEOS had a statistically significant . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.